Epithelix is a biotech company leader for in vitro assessment of drug efficacy and toxicity on human respiratory tract. Epithelix has developed unique 3D in vitro human airway tissues and testing services for studying airway pathologies like Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Diseases, Viral and Bacterial infections.

Within FAIR, Epithelix is responsible of in vitro assessment of aerosolized Flagellin toxicity on respiratory mucosa (WP2). As co-leader of WP3, Epithelix contributes to the characterization of flagellin’s protective effects on human cell-based airway models.

Visit Epithelix website

Samuel CONSTANT, Dr.

CEO